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ABSTRACT
The overall goal of this project was to develop, optimize, and test an ultrasoundresponsive targeted nanobubble for delivering osteoporosis-related silencing genes such
as Cathepsin K small interfering RNA (CTSK siRNA) for osteoporosis treatment. The
nanobubbles were synthesized using an in situ sonochemical method. The nanobubble
(NB) is composed of a gas core made from perfluorocarbon, stabilized with albumin,
encapsulated with CTSK siRNA, and embedded with alendronate (AL) for bone targeting
(CTSK siRNA-NB-AL). Following its development, the responsiveness of CTSK siRNANB-AL to a therapeutic ultrasound probe was examined. The results of biocompatibility
tests with human bone marrow-derived mesenchymal stem cells proved no significant cell
death (p>0.05). When the CTSK siRNA-NB-AL was supplemented with human osteoclast
precursors, they suppressed osteoclastogenesis. Thus, this project establishes the
potential of nanotechnology and ultrasound to deliver genes into the osteoclasts. This
research also presents a novel ultrasound responsive and targeted nanobubble platform
that can be used as a gene, drug, and/or oxygen delivery system for various diseases
including cancer, neurodegenerative diseases, or bone disorders.
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INTRODUCTION
1. Osteoporosis
Osteoporosis is a systemic skeletal disorder characterized by an imbalance between
bone-resorbing osteoclasts and bone-forming osteoblasts [1, 2]. A prominent indication
is a decrease in bone quality and mass, making people more susceptible to fragility and
fracture from low-energy trauma [3]. There are approximately 10 million cases of
osteoporosis in the US a year, with an additional 34 million Americans with low bone mass
putting them at a much higher risk for developing osteoporosis [4]. It affects women more
than men, where 37.7% of women and 10% of men currently suffer from osteoporosis not
including those with other underlying bone diseases such as spinal osteoarthritis [5]. The
US spends $10 to $17 billion a year on osteoporosis treatment, and the cost is expected
to increase past $22 billion by 2030 [4]. As none of the current therapies for osteoporosis
are without adverse effects, innovative therapies such as siRNA therapy for gene
silencing are required.

2. Challenges of siRNA Delivery
The clinical translation of siRNA delivery to humans has proven challenging [1, 6-9] due
to its large molecular size (~13 kDa) which makes it ineffective in penetrating the cell
membrane effectively [6, 9, 10]. Furthermore, naked siRNA directly injected into the
bloodstream or locally into the tissue are especially vulnerable to quick degradation and
off-site targeting resulting in immune responses with Toll-like receptors [6, 9].
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3. Ultrasound-Mediated siRNA Delivery
Ultrasound therapy is already clinically used and approved for internal tissues and bone
healing with the advantages of non-invasion and high safety [11], as indicated in Table
1. A highly notable side effect of ultrasound treatment is its therapeutic application of bone
regeneration and fracture healing [12, 13]. Specifically, low-intensity pulsed ultrasound
(LIPUS) is especially promising as mechanical energy in the form of acoustic pressure
waves transmitted through tissue, where the micromechanical strains caused by the
pressure waves in these tissues can result in biomechanical stimulation and biochemical
modification to induce bone regeneration [12, 13]. The rate at which this energy is
absorbed is proportional to the density of the tissue it is passing through [12]. LIPUS has
been approved by the FDA as a medical device and method to accelerate healing of bone
fractures [13-15]. It also simultaneously stimulates healing within bone defects and
distraction osteogenesis through increasing rate of angiogenesis [13, 14, 16, 17].
From the information gathered in the Table 1, ultrasound has the ability to release
drugs or genes from nanoplatforms by focusing the acoustic waves in a localized area
using a non-invasive procedure. This reduces the risk of surgeries or infections caused
by invasive procedures and allows for a much quicker and convenient procedure for the
patient with minimal risk. As highlighted in Table 1, the ultrasound procedure allows for
spatial and temporal control within millimeter precision allowing for a much more accurate
controlled drug release. Although it is noted that the heat produced by the beam does
increase the temperature, the intensity of the ultrasound used here has insignificant
impact on the temperature (p>0.05). When comparing the other stimuli-responsive
2

nanosystems, many have significant drawbacks due to patient-specific circumstances as
well as varying states of disease progression as shown in pH, ROS, and enzyme systems.
While they may have high selectivity and maintain a strong correlation with disease
states, endogenous stimuli-responsive drug delivery systems specifically involve many
unknown factors which are outside of the researcher’s control. For these reasons, the
ultrasound-stimuli-responsive system was chosen in my work.

Table 1. A summary of various stimuli responsive nanocarrier systems with their respective strengths and
weaknesses used in the literature for treatment of different diseases including bone disorders.

StimuliResponsive
Nanocarriers

Advantages

•
pH
•
•

•
•

•
•
•

Increased release of siRNA
Gene silencing
Release of cargo with high ROS
production

•

•

Can be used in cancer detection
and imaging due to abundance of
enzyme at disease sites
High selectivity

•

Enzyme
•
•
Thermo

•
Can be used dually with light or
temperature
Increased drug/gene release
Oxidation responsiveness using a
reactive oxygen species-sensitive
polymer
Increased cytoplasmic release of
drug/gene

Redox

ROS

Disadvantages

•

Very sensitive- very narrow
temperature range
Dosage can be precisely
controlled
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•
•

•

Large range of pH
in gastrointestinal
tract
Patient-specific pH
ranges
Effect of cell
surface thiols in
cellular uptake and
intracellular
trafficking
Complex
disassembly due to
cleavage of
thioketal linkages
Patient-specific
enzymes
Patient-specific
progression of
disease
Requires materials
used to be very
sensitive to
temperature

References

[18-20]

[18-20]

[19, 20]

[19, 20]

[18, 20]

•
Light

CO2

Ultrasound

•
•

Control of therapeutic molecules in
space and time
Ease of application
High biocompatibility

•
•

Controlled release
Nanoreactor that can insulate
different enzymatic reactions by
modulation

•
•

Non-invasive
Spatial and temporal control with
millimeter precision
Highly localized
Can kill tumor cells
Can regenerate the tissue
Can facilitate osteogenic
differentiation of stem cells
In-expensive
Available
Clinically approved

•
•
•
•
•
•
•

•

Low depth of tissue
penetration

•

Influenced by
temperature

•

Heat produced by
beam may interfere

[18, 20]

[20]

[18-20]

The most common types of ultrasound therapy utilized in literature are low intensity
pulsed ultrasound (LIPUS) [21-23], low intensity continuous ultrasound (LICUS) [24-26],
and pulsed focus ultrasound (pFUS) [27, 28]. Whereas LIPUS and LICUS are applicable
to large target organs such as bone, pulsed focused ultrasound is more specific to small
tumors and sensitive organs such as the pancreas [27, 28]. For these reasons, this project
will not use pulsed focused ultrasound and instead center around LIPUS and LICUS
applications.

4. Nanobubbles
Advantages of using nanobubbles (NB) over microbubbles (MB) in this particular study
becomes evident in the transport and ease of access to target cells. An intrinsic weakness
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of MB is their limited application as therapeutics due to their large size [29, 30]. This
prevents them from passing into the smaller endothelial gaps of blood vessels, and
without this, MB cannot be applied to increase the pervasiveness of the cell membrane
to enhance siRNA cellular uptake [29, 30]. However, NB are capable of crossing this
endothelial gap and enter the interstitial space of cells, generating greater significance
[29]. The ability of the NB to penetrate into the vasculature and remain after intravenous
injection places a high NB concentration due to accumulation in the target site, increasing
the permeability of the cell after ultrasound exposure [29, 31]. Sonoporation and cavitation
can be detected within the NB after low-frequency ultrasound is applied [29, 32].

5. Motivation and Significance
Without a controlled siRNA release mechanism, naked siRNA cannot diffuse freely across
the cell membrane barrier and has a finite half-life, deteriorating over time [10, 33]. This
is especially true when the dose of siRNA cannot be reapplied easily, carried to sites not
easily accessible, or biodegrades too quickly [33]. The capabilities of NB to passively
target and accrue within the cells and rupture under ultrasound exposure make NB a
particularly attractive vector for siRNA delivery.
I, therefore, have developed a novel nanoplatform of ultrasound-responsive
nanobubbles for targeted delivery of siRNA to osteoclasts (Figure 1). The packing of
siRNA into my nanobubble carriers to protect the siRNA from directly interacting with its
surroundings and slowing releasing it inside the cytosol provides the advantage of
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prolonging the gene silencing mechanism. This project is significant because it can shed
a new light for osteoporosis prevention and treatment, the nanoplatform developed
herein, and has a far reaching impact in treating other diseases including cancer.

Figure 1. Schematic Representation. A schematic representation of my ultrasound targeted nanobubble
expansion and destruction (UTNED) technology to facilitate CTSK-siRNA delivery into the osteoclasts for
treatment of osteoporosis through CTSK gene silencing. The nanobubble is composed of an albumin
protein shell with a perfluorocarbon (PFC) gas core containing Cathepsin K (CTSK) siRNA which I have
used due to its role in silencing the Cathepsin K gene, which causes osteoporosis. The nanobubble is
functionalized on the surface with Alendronate, a molecule which serves as a bone-targeting biomarker to
hone to osteoclasts. Through application of ultrasound (probe) the nanobubble grows and expands until it
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ruptures its contents into the cell, functioning by controlled sequential release where the optimal ultrasound
parameters can be modified by optimizing exposure time, intensity, frequency, and waveform to customize
to the severity of the disease (e.g. low intensity for superficial fractures vs high intensity for deep lesions).

6. Innovation
This project is novel because: i) I developed and optimized a new sonochemical method
for synthesis of targeted ultrasound-responsive nanobubbles, ii) I introduced two
procedures for therapeutic ultrasound induction including induction of ultrasound at
targeted site or induction before injection of nanobubbles which takes 3h for 95% rupture
of entire nanobubbles, iii) I discovered that my synthesis method can create a broad size
range of nanobubbles from 20-150 nm compared to previously synthesized nanobubbles
of 400-500 nm [29]. The range of sizes of my nanobubbles can facilitate cell
internalization, easily leak from the vasculature (in case of small nanobubbles <20 nm)
which can be an advantage for tumor therapy and sequential release of multiple genes,
iv) the previously established nanobubbles [29] has a very small gas core (<20 nm) which
does not allow for a high loading capacity into their nanobubble gas cores, v) my
procedure presents a simple method compared to their complex multi-synthesis
procedures, vi) my nanobubble is the first nanobubble platform that is responsive and
compatible with a clinically approved therapeutic ultrasound probe, vii) I established a
direct correlation between the ultrasound exposure time to nanobubble growth and
rupture, as well as ultrasound post-exposure time with nanobubble growth and rupture,
viii) I discerned the optimal ultrasound parameters by manipulation of exposure time,
7

intensity, frequency, and waveform for tunable expansion and rupture of my nanobubbles
for controlled siRNA release, ix) the manufacturing process of my nanobubbles is easy
(no need for extruder >$3000, polycarbonate membrane >$200, and liquid nitrogen),
quick (30 min), in-expensive ($23.30/100mg), stores easily (4°C), has a long shelf-time
(>3 months), environmentally friendly (no toxic chemicals), functionalizable (targeted
molecules; e.g. bisphosphonates I have used herein), and safe (biocompatible) with cells
(e.g. human mesenchymal stem cells and human osteoclasts I have used herein).
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MATERIALS AND METHODS
1. In Situ Sonochemical Synthesis of Cathepsin K siRNA-loaded Nanobubbles
(CTSK siRNA-NB)
To synthesize CTSK siRNA-NB, Cathepsin K siRNA (CTSK siRNA; 20 nM, Santa Cruz
Biotechnology), mixed with perfluorocarbon (PFC; 300 μL, FluoroMed) was added to
phosphate buffered saline (PBS; 4 mL, Gibco) containing human serum albumin (HSA;
40 mg, Sigma Aldrich). The mixture was sonicated with an ultrasonic probe
(Fisherbrand™ Model 120 Sonic Dismembrator) in an ice bath (30 s/15 s on/off, 200 W,
50% amplitude, 5 times). After a color change of the solution from colorless to white, the
obtained emulsion was ultracentrifuged (Optima XPN-100 Ultracentrifuge, Beckman
Coulter) at 15,000 rpm for 3 min at 22.5°C. The resulting CTSK siRNA-NB was later
washed in PBS 3 times before dispersion for further analysis.

2. Functionalization of CTSK siRNA-NB with Alendronate (AL) (CTSK siRNA-NBAL)
Alendronate sodium trihydrate (8.128 mg/mL, 25 mmol, Alfa Aesar) was dispersed in PBS
(10 mL). The mixture was placed in a Digital Ultrasonic Cleaner (Digital Pro) for 6 min at
55°C to increase the solubility of alendronate in PBS. CTSK siRNA-NB (0.015 g) was
added to the resulting solution. After 24-48 h at 4°C, CTSK siRNA-NB-AL was obtained
and centrifuged at 5,000 rpm for 5 min at 22.5°C, and washed 3 times with PBS before
storing at 4°C for further use.
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3. Characterization of Nanobubbles
3.1. Nanobubble Imaging with Transmission Electron Microscopy
Size of the NB alone and CTSK siRNA-NB-AL was measured using Transmission
Electron Microscopy (TEM; Jeol JEM-1011) by adding 2.5 μL of NB solution on a copper
grid (FCF- 3 400-CU, Electron Microscopy Sciences–EMS, Hatfield, PA, USA) as
previously described [34].
3.2. Nanobubble Size Distribution with Dynamic Light Scattering
The average size distribution of the NB alone and CTSK siRNA-NB-AL was analyzed
using dynamic light scattering (DLS). NB was diluted with PBS (10 mg/mL) to avoid
multiscattering and analyzed at 25°C with a Zetasizer Nano ZS90 (Malvern, UK). The
analysis was performed using the following setup: a material refractive index of 1.25; a
material absorption of 0.010; an dispersant refractive index of 1.336; and a medium
viscosity of 1.05 mPa s [34].
3.3. Detection of Surface Charge with Zeta Potential
A Zetasizer Nano ZS90 (Malvern, UK) was used to measure the surface charge (zetapotential, mV) of NB alone and CTSK siRNA-NB-AL. Measurements represented the
average of 3 batches with 10 runs per measurements [34].

4. Acoustic-Induced Nanobubble Growth and Rupture
Acoustic induction of nanobubbles at 25°C was performed using a New Pocket Sonovit
Portable Ultrasonic Therapy Device with 45 mm probe (Win Health Medical Ltd, Unit 1,
Oxnam Road Industrial Estate, Jedburgh, TD8 6LS). In order to stimulate nanobubble to
10

grow and rupture, NB (150 mg) were introduced into PBS (1.8 mL) at 25°C in 6-well
plates. The probe was placed underneath the well plate and paired with the plate using
Aquasonic Clear® Ultrasound Gel (Parker Laboratories, Inc., 4 Sperry Road, Fairfield,
NJ). Sound waves were applied using low-intensity continuous ultrasound therapy
(LICUS) and low-intensity pulsed ultrasound therapy (LIPUS). Parameters used for
LICUS were the following: output intensity (3 W/cm2), frequency (1 MHz), time (5 min),
and waveform (continuous). Parameters for LIPUS were output intensity (3 W/cm 2),
frequency (1 MHz), time (5 min), and waveform (pulsed on/off: 1/2). The total time needed
to treat the lesion was calculated using the following equation:
𝑇𝑖𝑚𝑒 = (𝑡) × (𝑆) × (𝑃𝑅) (Equation 1)
Where t is time (1 min), S is the number of times the ultrasound probe fits onto the lesion,
and PR is the pulse ratio [35].
The optimal parameter was determined to be 3 W/cm2 output intensity, 1 MHz
frequency, 5 min exposure time, and continuous waveform. Following the measurements
of nanobubble’s surface area as a function of ultrasound post-exposure time, the optimal
parameters where the most efficient nanobubble expansion and rupture occurred was
obtained after 5 min. The growth and expansion of NB was monitored using optical
imaging microscopy (AmScope 40X-2000X Biological Research Microscope with 5.1MP
Camera). Pictures and videos were captured to show progression of the NB’s growth and
rupture.
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5. Biodegradability of Nanobubbles
NB (100 mg) was suspended in PBS (9.9 mL) at pH 7.4 and incubated at 37°C. The
biodegradation degree was determined at day 1, 5, 9, 12, 15 using the following equation:
𝐵𝑖𝑜𝑑𝑒𝑔𝑟𝑎𝑑𝑎𝑡𝑖𝑜𝑛 𝑑𝑒𝑔𝑟𝑒𝑒 =

𝑊2 −𝑊1
𝑊1

× 100 (Equation 2)

where W1 is the initial weight (mg), and W2 is the weight at determined time i.e. day 1, 5,
9, 12, 15.

6. Protein Loading and Release from NB
L-tryptophan (Alfa Aesar) was used to measure the loading and release efficiency from
my nanobubbles. Tryptophan (204 mg) was mixed with PFC (300 μL), PBS (4 mL), and
HSA (40 mg) during the synthesis procedure described above. The tryptophan loaded NB
(T-NB) was then centrifuged at 15,000 rpm for 3 min at 22.5°C. The supernatant was
gathered carefully to assess the quantity of free tryptophan (unloaded to NB) using a
Nanodrop spectrophotometer (Nanodrop® ND-1000). The loading amount of tryptophan
could be obtained accordingly. Following the application of low intensity continuous
ultrasound (LICUS) (3 W/cm2 output intensity, 1 MHz frequency, 5 min exposure time,
and continuous waveform) on T-NB (15 mg), the T-NB was again centrifuged at 15,000
rpm for 3 min at 22.5°C. The supernatants were removed, and the amount of released
tryptophan present in the supernatant was measured using the NanoDrop
spectrophotometer. The release efficiency was then determined.
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7. Cytocompatibility of CTSK siRNA-NB-AL
After 1 and 7 days of incubation with CTSK siRNA-NB-AL (0.15 g), the viabilities of human
bone marrow derived mesenchymal stem cells (hBM-MSCs, ATCC PCS-500-012, 50,000
cell/well)) and human osteoclast precursors (hOCP, Lonza 2T-110, 10,000 cell/well),
were assessed using Live/Dead assay as we previously described [36]. Cells were
labeled using fluorescein diacetate (FDA; for live cells (green fluorescence), Thermo
Fisher Scientific, USA) and propidium iodide (PI; for dead cells (red fluorescence),
Thermo Fisher Scientific, USA) as the Live/Dead staining solution. The culture medium
was removed and the Live/Dead staining solution [FDA (75 μL/well) and PI (75 μL/well)]
was added and incubated with cells for 7 min at 37°C / 5% CO2. At the end of the
incubation time, the staining solution was removed and cells were washed 3 times with
PBS. Finally, the live cell imaging solution (Thermo Fisher Scientific, USA) was added to
each well (200 μL/well) before imaging. Images were acquired with a Zeiss LSM710 (look
at model) Confocal Microscope at a magnification of 10X and figures were created with
the FIJI software (ImageJ, GNU General Public License) to quantify live and dead
fluorescence in cells and obtain the percentage of live cells.

8. Osteoclastogenesis of CTSK siRNA-NB-AL
I used an established protocol for osteoclastogenesis of human osteoclast precursors
[37]. In brief, human osteoclast precursors (hOCP, Lonza 2T-110, 10,000 cell/well) and
osteoclast growth medium (10% FBS, 2mM L-glutamine, 100 units/mL penicillin, and 100
µg/mL streptomycin) were used. Following the culture of hOCP in osteoclast growth
13

media, the cell morphology was observed under a bright field and confocal imaging
microscope. As a control for osteoclast differentiation, hOCP with and without receptor
activator of nuclear factor ĸ B ligand (RANKL) was used.

9. Statistical Analysis
The following experimental groups were used: NB (n=4 or 5), NB-AL (n=4), and CTSK
siRNA-NB-AL (n=4), hBM-MSCs alone (n=4), hOCP alone + RANKL (n=4), and hOCP
alone - RANKL (n=4). The results were expressed as mean ± standard deviation (SD).
Statistical analysis of all quantitative data was performed using a one or two-way ANOVA
(analysis of variance) with post hoc Tukey test (Astatsa.com; Online Web Statistical
Calculators, USA) or unpaired Student’s t test with any differences considered statistically
significant when p<0.05 [38].
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RESULTS
1. Characterization of Nanobubbles
TEM results showed that the synthesized NB alone (Figure 2A-D) and CTSK siRNA-NBAL (Figure 2E-F) were 150±50 nm size with a spherical morphology and a PFC gas core.
The existence of CTSK siRNA and AL are also detected in TEM images (Figure 2E-F).
Using DLS, the NB size was shown to be 200±50 nm (Figure 2G). In addition, a single
sharp peak in my DLS result shows the uniform spherical shape of NB whereas an
irregular shape would have generated two or more peaks as previously shown [39]. When
testing the zeta potential of NB alone, an average surface charge of -21.05±3 mV was
obtained. The AL functionalization significantly changed the NB’s zeta potential to 15.9±0.833 mV (p<0.05). However, there was an insignificant change with the loading of
CTSK-siRNA in NB-AL at -14.6±0.709 mV (p>0.05).
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Figure 2. Microstructure Characterization of NB. (A-F) TEM images of NB in low (A-B) and high (C-D)
magnification showing the NB size (150±50 nm) and morphology (spherical); (E-F) TEM images of CTSK
siRNA-NB-AL showing a gas core made up of PFC contused with an albumin shell and functionalized with
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AL. (G) Results of DLS analysis of NB alone, NB-AL, and CTSK siRNA-NB-AL showing the size of 200±50
nm.

2. Protein Loading and Release Efficiency
The Nanodrop spectrophotometer was used to measure the quantity of free tryptophan
present in solution, revealing information about the amount of tryptophan loaded into the
nanobubbles (Figure 3). Since 204 mg of tryptophan was originally used in the synthesis
procedure and 89.1 mg of free tryptophan was measured before induction, the resultant
loading efficiency was calculated to be 56.3%. After induction (30 min), 184.6 mg of
tryptophan was found in solution, resulting in a 46.8% release efficiency. After induction
(1h), a 100% release efficiency was reached.
My rationale for utilizing tryptophan as a model protein to encapsulate within my
nanobubbles is due to its ease of detection by a Nanodrop spectrophotometer and costeffectiveness at higher concentrations. siRNA was difficult to detect unless completely
undiluted in which case it is costly. For these reasons, tryptophan was selected to
simulate the loading and release efficiency of siRNA.
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Figure 3. Loading and Release Efficiency of Protein from NB. Result of Nanodrop spectrophotometry
of tryptophan loaded into and released from NB at 280 nm absorbance.

3. Ultrasound Responsiveness of Nanobubbles: Effect of Exposure Time, Intensity,
and Waveform
To determine the optimal parameters for ultrasound exposure on nanobubbles, different
variables (waveform, intensity, and ultrasound exposure time) were manipulated under
controlled conditions. A series of experiments were carried out with varying LICUS and
LIPUS waveforms under both 1 W/cm2 and 3 W/cm2 intensities over 0-15 min time
increments of ultrasound exposure time (Figure 4). The optimal parameter should convey
the gradual growth, expansion, and rupture of the nanobubbles with increase in
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ultrasound exposure time; a criteria most successfully accomplished with LICUS
waveform, 3 W/cm2, and 1 MHz frequency. From 0-15 min, the nanobubbles under this
parameter show visible and continuous growth until eventual rupture in a linear
progression. This is evident by the increasing size of the nanobubbles from 20 nm at 0
min to 200 nm at 5 min to 500 nm at 13 min until rupture at 15 min, where only the shell
remains.
Additionally, the gas core of these nanobubbles expand significantly with increased
ultrasound exposure time. At 5 min, the gas core is very small (10 nm), whereas by 13
and 15 min, the core has expanded to 80 and 100nm, respectively, to take up the majority
of area inside the nanobubble, leaving a thin outer shell as it is pushed outward. This
increased tension and increasingly porous shell creates a pathway for nanobubble
rupture and collapse, providing an efficient method for delivery of genes and drugs via a
nanobubble platform.
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Figure 4. Ultrasound Responsiveness of NB. The effect of various ultrasound parameters include
waveform (LICUS vs LIPUS), intensity (1 vs 3 W/cm2), and ultrasound exposure time (0-15 min).

4. Ultrasound Responsiveness of Nanobubbles: Effect of Post-Exposure Time
After identifying the optimal ultrasound parameters, the length of exposure time must be
further refined to be clinically relevant. To elucidate this information, two time points were
utilized: 5 min and 9 min. After these respective lengths of ultrasound exposure time,
bright field microscopy images of the nanobubbles were taken over 0-180 min to capture
the progressive changes. For both time points, no significant differences were seen during
the growth to rupture progression of the nanobubbles (5 min exposure time: 100±10 nm
(Figure 5A) to 1000±250 nm (Figure 5E) to 0±100 nm at collapse (Figure 5F) vs 9 min
exposure time 120±10nm (Figure 5G) to 1000±250nm (Figure 5J) to 0±50nm at collapse
(Figure 5L); p>0.05).
Similar to the previous experiments conducted on the effect of various ultrasound
parameters over different ultrasound exposure times on nanobubbles, the porosity of the
nanobubble shell intensified as the post ultrasound exposure time increased. This
porosity is distinctive when analyzing the size of nanobubbles. As seen in both 5 and 9
min trials (Figure 5), the nanobubbles grew from 100±10 nm and 120±10 nm,
respectively, to 1000±250 nm before collapsing at 0-50 nm. The gas cores in both
experiments also reflected the nanobubble’s enlargement, as gas cores in Figure 5E and
Figure 5K are noticeably larger at approximately 500 nm (p<0.05).
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Based on this data, 5 min of ultrasound exposure time was ultimately selected to
prevent prolonged effects. However, in animal and clinical applications, the durability of
bone tissue may deem 9 min a more suitable option. Through testing of both 5 and 9 min,
I can optimize to the situation presented.
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Figure 5. Responsiveness of NB to Ultrasound Post-Exposure Time. The induction of LICUS for 5 (AF) and 9 (G-L) min exposure time resulted in insignificant changes in NB sizes (p>0.05). The length of postexposure time over 0-180 min showed the significant incremental size increase which led to the complete
ultrasound targeted nanobubble expansion and destruction (UTNED) for both 5 (A-F) and 9 (G-L) min
exposure times (p<0.05).

5. Biodegradability of Nanobubbles
NB alone was suspended in PBS at pH 7.4 and incubated at 37°C for 15 days. The results
showed the biodegradation degree of NB was 0% (day 1), 0.2% (day 5), 7.3% (day 9),
16.8% (day 12), and 21.2% (day 15).

6. Biocompatibility of Nanobubbles
6.1 Cell Morphology
To test the biocompatibility of my nanobubbles, they were cultured with hBM-MSCs. As
shown in Figure 6, the introduction of the nanobubbles had no significant impact (p>0.05)
on the morphology of the cells, which retained their spindle-like elongated nature. The
nanobubbles, highlighted by the white arrows, are present among the hBM-MSCs (Figure
6A-F) and do not appear to cause cell death or decrease cell confluency. Growth and
division of the cells remain normal when compared to the cell alone (Figure 6G).

23

Figure 6. NB Biocompatibility. Bright-field microscopy imaging of NB alone (A-B), NB-AL (C-D), CTSK
siRNA-NB-AL (E-F), cultured with hBM-MSCs before (A, C, E), and 30 min after induction (B, D, F) at day
0. As a control hBM-MSCs alone was used (G). The white arrow indicates the presence of NB.

After 7 days of cell culture with hBM-MSCs (Figure 7), the biocompatibility of the
nanobubble trial groups as compared to that of the cell alone trial group continue to be
comparable. All experimental groups showed 90-98% confluency and morphology of the
cells continue to be healthy in a spindle-like elongated form.
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Figure 7. NB Biocompatibility. Bright field microscopy imaging of NB alone, NB-AL, CTSK siRNA-NB-AL,
cultured with hBM-MSCs at day 7 in low and high magnifications are shown. As a control, hBM-MSCs alone
was used.

6.2 Cell Survival
The biocompatibility of my nanobubbles with hBM-MSCs was further verified with
confocal microscopy. In Figure 8, the cell alone group showed 95% confluency (Figure
8A-C), NB Alone showed 90% confluency (Figure 8D-F), NB-AL showed 98% confluency
(Figure 8 G-I), and CTSK siRNA-NB-AL (Figure 8J-L) showed 98% confluency,
confirming no drastic changes (p>0.05) to biocompatibility. The quantity of dead cells
(Figure 8B, E, H, K) make up less than 1% of the total number of cells, signifying that the
nanobubbles pose no threat to the health and growth of hBM-MSCs.
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Figure 8. NB Biocompatibility. Confocal microscopy imaging of cell alone as control (A-C), NB alone (DF), NB-AL (G-I), CTSK siRNA-NB-AL (J-L), cultured with hBM-MSCs after induction at day 7. Live cells =
green (stained with FDA), dead cells = red (stained with PI).

7. Cellular Uptake of Nanobubbles
The internalization of the nanobubbles into hBM-MSCs was visualized in Figure 9.
Although the majority (approximately 95%) of nanobubbles have ruptured after 3h of
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ultrasound induction to the nanobubbles, a small portion (approximately 5%) of
nanobubbles may not have yet ruptured due to other underlying factors such as delayed
expansion of the nanobubbles because of their very small sizes (<10 nm).

These

nanobubbles (CTSK siRNA-NB-AL) are shown here internalized into the hBM-MSCs as
small spherical dots as indicated by the white arrows (Figure 9C, F). With 98-99%
confluency, the hBM-MSCs have no notable changes to their morphology.
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Figure 9. NB Internalization. (A-F) Confocal microscopy imaging of hBM-MSCs cultured with siRNA
CTSK-NB-AL after induction at day 7. Live cells = green (stained with FDA), dead cells = red (stained with
PI). The white arrow indicate NB internalized into the cells.

8. Nanobubble Suppression of Osteoclastogenesis
Bright field microscopy on Day 0 (Figure 10) shows the presence of nanobubbles
(depicted by the white arrows) (Figure 10E-H) among the hOCP. The morphology of the
hOCP across all experimental groups remain unchanged (spherical).

29

Figure 10. NB Suppression of Osteoclastogenesis. Bright field imaging of hOCP alone (A-D) or hOCP
cultured with NB alone (E-F), and CTSK siRNA-NB-AL (G-H) after induction at day 0 at low and high
magnifications. The white arrows indicate NB. hOCP with RANKL as a positive control (A-B) and without
RANKL as a negative control (C-D) were used.
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After 7 days, bright field microscopy showed significant differences in cell
morphology (p<0.05). For the NB alone (Figure 11A-D) group, osteoclasts (shown with
red arrows) were seen as large dome-shaped multinucleated cells comprised of fused
mononuclear hOCP, similar to that of previous literature for osteoclast morphology [40].
This indicates that the presence of NB alone with no Cathepsin K siRNA for
downregulation of the Cathepsin K gene does not inhibit the formation of osteoclasts.
However, the CTSK siRNA-NB-AL (Figure 11E-H) group, had few to no hOC formation
and remained in their hOCP state, as shown with black arrows, validating the role of CTSK
siRNA in suppressing osteoclastogenesis.

Figure 11. NB Suppression of Osteoclastogenesis. Bright field imaging of hOCP cultured with NB alone
(A-D), or CTSK siRNA-NB-AL (E-H) after induction at day 7 at low (A-B, E-F), and high (C-D, G-H)
magnifications. The black arrows indicate hOCP and the red arrows hOC.

The confocal imaging conducted on the Day 7 mirrored the results obtained with
bright field imaging with the presence of hOC in the NB alone group (Figure 12M-R) and
the absence of hOC in the CTSK siRNA-NB-AL group (Figure 12S-X). As seen in Figure
12, there was less than 1% cell death in the positive and negative control groups (Figure
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12A-L), whereas the NB alone group (Figure 12M-R) had an average 5-10% cell death
and the CTSK siRNA-NB-AL group (Figure 12S-X) had an average 10-15% cell death.
NB alone contained an average of 2.5 hOC/mm2, however, using CTSK siRNA-NB-AL
significantly reduced the osteoclastogenesis to 0.1 hOC/mm2 (p<0.05).
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Figure 12. NB Suppression of Osteoclastogenesis. Confocal microscopy imaging of hOCP alone (A-L)
or hOCP cultured with NB alone (M-R), and CTSK siRNA-NB-AL (S-X) after induction at day 7. hOCP with
RANKL as a positive control (A-F) and without RANKL as a negative control (G-L) were used. Live cells =
green (stained with FDA), dead cells = red (stained with PI).
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DISCUSSION
1. Current Therapies for Osteoporosis
Existing therapeutic strategies aim to inhibit bone resorption using antiresorptive agents
or enhance the formation of bone using anabolic drugs [9]. The antiresorptive drugs
suppress osteoclast activity in order to preserve bone mass and increase bone strength;
whereas the anabolic drugs attempt to induce bone formation by simultaneously
increasing bone mass and reversing bone degradation [41]. Among these antiresorptive
agents are bisphosphonates, estrogens, calcium, vitamin D, selective receptor
modulators, and denosumab, which are currently clinically available [1, 2, 9, 41].
Bisphosphonate, a common treatment for women 65 and older with a low bone density,
costs $66,733 per year which includes a 10-year risk of hip fracture probability that could
cost up to $60,000 [42, 43]. Furthermore, treating all eligible women with a
bisphosphonate would cost $5.6 billion to result in 390,049 fewer fractures [43].
Parathyroid hormone (PTH) therapy is another current alternative to induce
anabolic effects on bone formation, which stimulates the mechanism of osteoblasts by
binding to a specific receptor and activating signaling pathways [1, 2, 9, 41]. However,
various drawbacks have arisen from antiresorptive drugs like bisphosphonate where its
long term use has been shown to induce jaw osteonecrosis and abnormal long bone
fractures [1, 9]. Even as the most clinically used antiresorptive drug, bisphosphonate is
not readily absorbed from the gastrointestinal tract meaning that high doses are
necessary, leading to greater gastrointestinal problems [1, 41]. These limitations center
around issues of bioavailability and toxicity [1, 41]. Even with PTH therapy, there is
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possible limited efficacy on nonvertebral bone fractures and activation of bone resorption
due to promotion of osteoclastogenesis resulting in chronic exposure that counteracts its
anabolic purpose of promoting bone formation [1, 9, 41]. Due to these limitations, novel
therapies must be implemented.

2. RNA Therapies
Mammalian cells contain an endogenous RNA interference (RNAi) pathway which is a
viable mechanism for regulating signaling pathways within cells by modulating level of
gene expression [6]. This RNAi does not involve DNA and can bypass processes in the
nucleus and conduct transport through the nuclear envelope [9]. Because sequencespecific small interfering RNAs (siRNA) is a portion of the RNAi complex, they are able to
“silence” specific gene expression having complementary strands, creating great interest
in their ability as a therapeutic [6]. The ability of an siRNA therapeutic to target virtually
any gene based on knowledge of the messenger RNA (mRNA) sequence provides a
strong advantage over traditional drugs [6, 8]. The goal of this therapy is to utilize siRNA
to target and cleave the complementary mRNA to silence the gene effectively [7]. The
therapeutic potential of using this therapy is promising and can expand to various
diseases ranging from osteoporosis to cancers [8].

3. siRNA Delivery
3.1 Challenges
The clinical translation of siRNA delivery to humans has proven challenging [1, 6-9]. The
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pharmacological properties of siRNA mean that its high anionic charge density (38-50
phosphate groups) and large molecular size (~13 kDa) make it ineffective in penetrating
the cell membrane effectively [6, 9, 10]. Naked siRNA directly injected into the
bloodstream or tissue are especially vulnerable to quick degradation and off-site targeting
resulting in immune responses with Toll-like receptors [6, 9]. Furthermore, siRNA
administered systemically requires crossing the vascular endothelial barrier before
diffusing through the extracellular matrix, while avoiding kidney filtration and non-targeted
cell internalization [6]. Even after the siRNA has been up-taken into the targeted cell, they
need to be released from endosomal compartments and reunite with the RNAi machinery
[6]. siRNA must also maintain resistance to nuclease degradation to properly function
because of their short half-lives of less than 6 min when exposed to serum nucleases [6,
7]. All of these measures contribute to the significant challenges that need to be overcome
when developing a therapeutic for efficient siRNA delivery.
3.2 Potential Solutions
Due to the variety of biological mechanisms of RNAi transfection, delivering the plasmid
DNA and siRNA to the appropriate intracellular targets is crucial to establish the intended
effects of the desired therapeutic [44, 45]. A primary interest is to regulate the kinetics of
siRNA release in a way that the duration of gene silencing can be maintained and/or
controlled without need for repeated treatments [33]. Controlled delivery of nucleic acids
ensures the plasmid DNA is transported to the nucleus for expression and the siRNA is
released to eliminate translation of a targeted gene, keeping the siRNA concentration
above the critical threshold for a longer length of time [10, 44-46].
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4. Cathepsin K gene
Various osteoporosis-causing genes were carefully summarized and weighed according
to their benefits and drawbacks (Table 2). Among these, Cathepsin K (CTSK) proved to
be the most promising and was therefore studied in my research. CTSK addressed many
obstacles affecting other genes, such as durability for long term use, lower reactivity but
higher potency in biological systems, and specificity to siRNA studies in osteoclasts [47].
The shortcomings of CTSK were also resolved with the use of mouse-specific and
human-specific strains of Cathepsin K siRNA. This allowed me to negate any organismal
differences in interactions with the siRNA. Using the knowledge gathered, CTSK was
chosen as the gene targeted.

Table 2. The summary of the rationale for selection of Cathepsin K gene for targeted site versus other
osteoporosis-inducing genes.

Genes

Advantages
•

Histone
Deacetylase 5
(HDAC5)

•
•
•
•

Osteoclastogenesi
s Inhibitory Factor
(OCIF) or
Osteoprotegerin
(OPG)

•

Have cell type-specific
expression patterns
Replicable
Widely used in siRNAmediated knockdown of
HDAC5
Accessible
siRNA systems have also
been developed for
regulating osteoprotegerin,
specifically for breast cancer
and osteoblastic
differentiation
siRNA delivery specific to
osteoprotegerin protects
cardiomyocytes when
released from adiposederived stem cells
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•
•

•

•

•
•

Disadvantages

References

Weakly expressed in
liver
Not detected in
osteoclasts

[48-58]

OPG and receptor
activator of nuclear
factor ĸ B ligand
(RANKL) are linked
Polymorphisms could
occur when
administering
osteoprotegerin
Expensive
Not very common

[59-68]

•
LDL Receptor
Related Protein 5
(LRP5)

•

•
•
•
Sclerostin

•

•
•
Cathepsin K
•

Previously used siRNA to
block LRP5 in osteoarthritic
chondrocytes
Targeting LRP5 also impacts
other malignant diseases like
sclerotic bone metastasis and
myeloma
Common
Human sclerostin has been
used in immunizations
Sclerostin expressed nearly
exclusively in osteocytes
Previous use of lipid
nanoparticle delivery of
siRNA to silence SOST and
inhibit sclerostin in vivo
Human osteoclastomaderived osteoclastsphenotypically identical
Good for long-term use due
to less-reactive, more potent
reversible inhibitors of
Cathepsin K
Used with siRNA in primary
human osteoclasts

•
•
•

•
•
•
•

•

•

Increased signaling and
potential for malignant
cases
Polymorphisms are
possible
Specific mechanism
that affects signaling
activity not clearly
studied
Mechanism of anabolic
pathway unclear
No accurate estimate
for optimal treatment
duration
Long term use not
certain
No evidence on
antifracture efficacy
Mouse strains- differ in
bone mass, more
susceptible to bone
loss compared to
humans.
Different estrogen
response

[69-74]

[75-80]

[47, 81-86]

5. Therapeutic Ultrasound
My rationale for using ultrasound was due to its effect on nanobubble expansion and
destruction for siRNA release, and its ability to cause vibration to the site which induces
formation of vascular networks and vessels while promoting bone healing and
regeneration of damaged bone tissue.

6. Perfluorocarbon-Based Nanobubble
Perfluorocarbon was used due to its capabilities as a biocompatible and ultrasoundresponsive material. It also can function as an oxygen carrier to release oxygen to the
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tissue, supporting tissue regeneration or oxygenating cancer cells to prevent their hypoxia
[87]. Each material and method used were specifically chosen to maximize the positive
implications they have on bone tissue (Table 3).

Table 3. A summary of the rationale for selection of perfluorocarbon as the gas core of my ultrasoundresponsive nanobubbles. Clinical trials retrieved from clinicaltrials.gov

Type of
UltrasoundResponsive
Nanobubble
Used

Advantages

•
Mesoporous
Silica

•
•
•

Gold (Alginate
Capsules)

Calcium
Carbonate
Multilayer

•

•

•
Poly(lactic-coglycolic acid)
(PLGA)

•

High
biocompatibility
Mechanical and
chemical stability
High loading
capacity
Retain payload for
up to a week
Release payloads
with intensity and
duration
Large quantity of
encapsulated
macromolecules
without losing
biological activity
No volume
expansion at low
acoustic pressure
Shells intact until
reaching specific
pressure threshold
of ultrasound
reached

Disadvantages

•
•

•

•

•

Difficult to control
release of drug
Non-degradable

Clinical Trials

N/A

References

[88, 89]

Has not been
tested after
functionalizing

NCT03103802
NCT03196583
NCT01226563

[89]

Not as suitable for
encapsulating
drugs with low
molecular weights

NCT01857154
NCT01005381

[90]

Difficult to
stimulate local
drug release

NCT03060655
NCT03474627

[91]
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•

•
Perfluorocarbon
•
•
•
•

Rapid drug release
due to
simultaneous
expansion and
nanosphere rupture
Capable of
intensive drug
delivery
Previously used in
siRNA therapy
Oxygen carrier
(oxygen nanotank)
Highly
biocompatible
Biodegradable

•

The need for
sonicator (e.g.
Fisherbrand™
Model 120 Sonic
Dismembrator)

NCT01391481
NCT01604616
NCT00407108

[92]

7. Delivery Systems
There are several common delivery systems as summarized in Table 4. However, I
selected to synthesize and test nanobubbles because i) they can be internalized into the
cells due to their smaller sizes compared to microbubbles, ii) they can deliver genes such
as the CTSK siRNA used herein on demand (e.g. using ultrasound only), and iii) they are
safe, highly stable, and inexpensive with a high shelf-life, iv) they are highly marketable
with a low manufacturing price (<$25), low manufacturing time (<1h), with commercially
available chemicals and equipment in a safe and accessible manufacturing environment,
and v) there is a wide range of nanobubble sizes providing a great advantage for
sequential release of drugs/genes.
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Table 4. The summary of the rationale for selection of nanobubbles-based delivery system versus the
common microbubbles and gene-activated matrices.

Type of Delivery
System

Advantages

Disadvantages
•

•
Microbubbles

Gene-Activated
Matrix

•

Capable of passing
through pulmonary
capillaries
Delivery of siRNA into
cytosol without the
endocytosis pathway

•
•

Safe
In-expensive

•

Can accumulate in tumor
tissues with passive
targeting due to nano size
Injectable
Can diffuse through cell
membrane
Sensitive to ultrasound
Gene/drug delivery on
demand
Can leave the
vasculature of leaky
vessels in the tumor for
facilitating the
accumulation
Small volume is required
for injection compared to
microbubble
Trackable with
commercial ultrasound
imaging
High stability and shelflife
Safe and in-expensive
synthesis procedure

•
•
•
•
•
Nanobubble
•
•
•
•

•
•
•
•
•
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Low stability of microbubbles
due to high solubility of air in
blood
Large volume is required for
injection
Large micrometer size
Short circulation time
Low injectability
Low cellular uptake

References

[91, 93]

•

Lack of spatiotemporal
control

[94]

•

The possible generation of
reactive oxygen species (but
it can be adjusted based on
the size of the gas core in
the synthesis procedure)

[91]

8. Mechanism of Ultrasound Targeted Nanobubble Expansion and Destruction
(UTNED)
Low-frequency ultrasound exposure deliver high energy to nanobubbles for expansion,
inducing holes up to 50 nm in diameter at a half-life of 20-50 ms on the surface of the
nanobubble in a process called “sonoporation” [29, 95]. Sonoporation also increases the
cell uptake of drugs and genes that have been administered through ultrasound targeted
nanobubble expansion and destruction (UTNED) [11, 29, 95, 96]. Ultrasound-enhanced
delivery allows for cavitation of NBs due to the pressure of oscillations, causing the NBs
to violently collapse to release siRNA above a specific threshold called inertial cavitation
[97, 98].

9. Limitations and Future Plans
The limitations of my study include a i) lengthy synthesis optimization procedure, ii) the
requirement of performing the synthesis procedure in special facilities such as fume hood
and an expensive sonicator equipment, iii) low loading efficiency at 56.3% for tryptophan
(The loading efficiency of siRNA should be different than that of tryptophan due to the
different surface charges. In the future, I plan to further optimize my synthesis procedure
to maximize NB loading to over 80% for siRNA - the loading efficiency of therapeutics
depends greatly on the surface charge; the zeta potential of NB had a surface charge of
-21.05±3 mV, while the surface charge of siRNA is − 4.7 ± 3.7 mV [99] and the zeta
potential of tryptophan is >–30 mV [100] . These differences in zeta potential may help to
enhance loading of siRNA into the nanobubbles due to the higher absorption at different
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charges, and iv) lack of performing in-depth cell and molecular biology studies on my
nanobubbles (I plan to conduct a

gene expression study of osteoclasts during

osteoclastogenesis using Western blot and an in vivo study on my nanobubbles). An
animal protocol has been approved for my

future study (IACUC Protocol

#PROTO202000048) on ovariectomized mice models to study the safety and efficacy of
my nanobubbles.
Since PFC also releases oxygen as a byproduct, it may stimulate bone regrowth
with sufficient oxygen to the osteoporotic site and prevent ischemia, creating a dual
oxygen/siRNA delivery nanoplatform. While applying LICUS and LIPUS parameters as
described above, an oxygen sensor available in my lab (PreSens) will be used to measure
the amount of oxygen released from the nanobubbles. The resulting data will be modelled
in a graph to show the oxygen release vs. time before, during, and after each trial. These
nanobubbles can also be used as oxygen nano shuttles to deliver oxygen to cancer,
prevent tumor hypoxia, and improve responsivity to chemo, radiation, or photodynamic
therapy. Oxygen delivery can also help with tissue regeneration and wound healing.
Other genes, drugs, and/or growth factors can be encapsulated into my
nanobubbles for targeted cancer theranostics. Regenerative genes such as vascular
endothelial growth factor (VEGF), bone morphogenetic proteins (BMP), and hepatocyte
growth factor (HGF) can be incorporated into the nanobubbles for promoting
angiogenesis and tissue regeneration. Different targeting biomolecules can also be
functionalized onto the nanobubbles for targeting to the cells of interest.
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The quantification of NB internalization into hOCP and siRNA imaging into the cells
will also be carried out. Initial conversations have begun with several research labs (Dr.
Kiminobu Sugaya’s lab and Dr. Melanie Coathup’s lab) at the Burnett School of
Biomedical Sciences. The collaboration with Dr. Sugaya will result in the use of my
optimized nanobubble platform for gene delivery to treat neurodegenerative diseases
such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis
(ALS). Their lab would functionalize my nanobubbles with brain homing peptide (BHP)
and encapsulate them with genes such as small hairpin RNA (shRNA) to target neural
cells and bypass the blood brain barrier. Additionally, Dr. Melanie Coathup, is working
with me to similarly use the nanobubbles to deliver a new drug for treatment of
osteoporosis.
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CONCLUSION
In summary, I developed and optimized an ultrasound responsive targeted nanobubble
platform that can deliver CTSK siRNA to osteoclasts. My results showed that these
nanobubbles can safely reduce osteoclastogenesis and therefore can be used for
osteoporosis treatment. This ultrasound responsive targeted nanobubble has a broader
impact in treating other diseases including cancer, neurodegenerative diseases, bone
disorders, as well as play a crucial role in oxygen-generating implant technologies and
regenerative medicine.
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APPENDIX
Failed Attempts
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1. Failed Attempts
1.1 Synthesis
Prior to discovering the finalized synthesis procedure as stated within the Materials and
Methods section, there were approximately 8 months of inconclusive results and failed
NB attempts. Over these months, I confirmed there was no formation of nanobubbles
using the following synthesis materials: i) PFC alone (3 mL), ii) PFC (7.5 µL), NaOH (1.25
mL), and C2H5OH (1.25 mL), iii) PFC (1.5 mL), NaOH (6.5 mL), and C2H5OH (2.5 mL),
iv) PFC (1.5 mL), NaOH (6 mL), and C2H5OH (2.5 mL), and v) PFC (250 µL), NaOH (5
mL), and C2H5OH (5 mL). Two examples of failed nanobubble synthesis attempts are
depicted below.

A successful synthesis procedure typically results in an evenly distributed cloudy
white mixture that remains stable when sonication has stopped. However, as shown in
the images above, there was a distinct separation of layers and an uneven distribution
post-sonication. An essential material, human serum albumin, was also missing from the
beginning trials, leading to no formation of nanobubbles as they could not be stabilized
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with a protein shell. PBS also replaced the C2H5OH originally used which resolved
solubility issues.
1.2 Polydopamine Coating
Initially, I had planned to include a polydopamine coating on the surface of the
nanobubble for its ability to stabilize the structure and serve as a sticky surface for
alendronate to functionalize upon. However, after several weeks of attempting this, only
images such as the one below resulted. While the polydopamine coating procedure was
successfully performed, the nanobubbles appear to have collapsed due to the additional
interaction with polydopamine and have not formed spherical bubbles. Severe
aggregation of the nanobubbles in the images shown below led to unresponsiveness with
therapeutic ultrasound.

Despite the lack of polydopamine coating within my current nanosystem described
herein, I have shown successful functionalization, gene internalization, and subsequent
ultrasound responsiveness of my nanosystem, proving that polydopamine was not
needed. In fact, the presence of polydopamine seemed to hinder the stability, cause
agglomeration, and prevent diffusion of sound waves to the PFC core of my nanobubbles,
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while its absence created a nanosystem that was stable, functionalizable, and highly
ultrasound-responsive.
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